Precision Medicine Track Day One

 

Precision 2018 Day 1

08:00 Registration opens

08:50

Welcome from Terrapinn

Opening Keynotes: Implementing precision medicine into clinical practice

Sue Hill
09:00

Implementing precision medicine in large scale public health systems

Joanne Hackett
09:25

Individualised medicine, and using the genome and digital technologies to understand disease and prevention

  • The value of genomics in healthcare
  • How Genomics England is catalysing the UK genomics landscape
  • How genomic data can diagnose and treat disease
  • Opportunities unique to the UK and why the time is now for harnessing the ecosystem
Panel discussion
10:15

Reserved for supporting partner

Please contact Erica Baeta +44 (0)207 092 1152, erica.baeta@terrapinn.com or Derek Cavanagh +44 (0)207 092 1297, derek.cavanagh@terrapinn.com for further details

10:40 Networking Break

Diagnostics

Big Data and Genomics

Infrastructure and Investment

Diagnostics
11:40

Whole genome sequencing as a powerful clinical tool to treat cancers with an HPV etiology

  • Different types of whole genome sequencing- Illumina versus BGI
  • Importance of HPV integration to the eventual cancers that develop
  • Important clinical information gained from whole genome sequencing
  • How WGS information can drive the liquid biopsy
Big Data and Genomics
11:40

Creating a digital health strategy; An informatics journey

  • Semantics and Metadata
  • Data catalogs and federated data/analytics
  • Data Governance
  • Using the principles of FAIR data
Infrastructure and Investment
11:40

Advancing innovation in personalised medicine through public private partnerships: The innovative medicines Initiative

  • Technology in the post human genome world is driving new disease taxonomies of disease and therefore new pathways for intervention
  • For some complex diseases like Alzheimer’s Disease, Type 2 Diabetes or Cancer, early stage developments can be achieved with lower risk and lower costs through PPPs
  • Patient engagement at early stages of R&D is critical for overall success
  • Bringing all stakeholders to the table including health economists, regulators, payers as well as Academics, Clinicians, SMEs, Patients and industry players is crucial for dealing with complex disease
Diagnostics
12:00

Some recent advances in host biomarker approach to precision medicine

  • Precision medicine can benefit from validated host biomarkers
  • Validation of host protein and nucleic acid biomarkers for key public health priorities
  • Probable risk, prognosis, diagnosis, treatment response are key considerations for patient stratification
  • Recent examples of advances in biomarker discovery, validation, translational and commercial development
Big Data and Genomics
12:00

Oncology – whole genome sequencing

  • IT challenges
  • Big data approaches
  • Molecular tumour board
  • Whole genome sequencing
Infrastructure and Investment
12:00

Funding the future through impact investing

While many investors are primarily concerned with returns on investment, many investors and organizations are more dedicated to social returns through the application of capital. In this interactive session, we will discuss various funding sources such as:
  • Traditional venture capital
  • Family Offices and High Net Worth Individuals
  • Government sponsored programs
  • Foundations and Nonprofits
Diagnostics
12:20

Cloud and security services to manage your big data

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Diagnostics
12:20

cMyC - how a novel biomarker could transform chest pain triage

  • Cardiac Myosin-binding Protein C (cMyC) is a novel biomarker of myocardial injury.  Over the past 20 years, cardiac Troponin has transformed emergency care around the world
  • Our research demonstrates that cMyC is more abundant than the Troponins and at least as good as the leading Troponin assays in directing immediate triage of patients presenting with suspected acute non-ST elevation myocardial infarction.
  • This property, combined with the analytic sensitivity of our assay, suggests we can detect myocardial injury on a point-of-care platform; thus, improving cardiovascular care for millions of people
Diagnostics
12:40

Next generation sequencing and how it will transform your diagnostics

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Big Data and Genomics
12:40

Enablers for scaling up access to big health data

  • The challenges with accessing and combining health data sets at scale
  • Establishing trustworthy governance and privacy protection solutions
  • Data discovery and best practices in data sharing
  • Promoting the adoption of interoperability standards and data quality improvement
  • Demonstrating value to society from reusing their health data for research

13:00 Networking Lunch

Diagnostics
14:30

Chemical sensing microchip technology for liquid biopsies in breast cancer

  • Latest advances in chemical sensing microchip technology currently being used for genomics and point-of-care diagnostics
  • Recent and exciting results of our research towards the development of a sample-to-result, scalable, Lab-on-Chip system for early detection of breast cancer recurrence
Big Data and Genomics
14:30

Will computers be the better doctors soon? Real-world insights from oncology

  • How oncologists already benefit from interdisciplinary cooperation beyond doctors
  • When time matters: flexible real-time data analysis of big medical data at your fingertips using the AnalyzeGenomes.com platform
  • Application examples:
  • Accessing latest international medical expertise through the medical knowledge cockpit to enable personalized therapy decisions
  • Introducing next-generation sequencing to the clinical routine through reproducible high-throughput data processing
  • Individual assessment of available drugs through interactive drug response analysis
  • Enabling patients to manage their personal health data in a holistic way and support medical research at the same time through the data donation pass
Infrastructure and Investment
14:30

Accelerating precision health for all of us: the all of us research program

  • Provide an overview of the NIH All of Us Research Program
  • Describe the Infrastructure for digitally driven research resource, from participant engagement to data access
  • Describe data collection plans for enabling precision medicine research
Big Data and Genomics
14:50

The use of technology for pharmaceutical workloads

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Infrastructure and Investment
14:50

Panel: Funding precision medicine – how to fund your projects

  • What are investors most likely to find compelling in an elevator pitch?
  • Is it the science or the team that attracts capital?
  • How can I obtain access to funding sources?
  • What are the benefits and drawbacks of each capital source?
Diagnostics
15:10

Using lab developed tests for companion diagnostic development

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Big Data and Genomics
15:10

Integrating clinical and genomic information

  • SMART/FHIR Genomics
  • Stakeholders and users
  • Apps, services, and servers
  • Pilots, implementations, and conformance testing

Collaborations across precision medicine

Big Data and Genomics
15:30

User Experience for Life Science (UXLS): current trends in life science software development that can enhance research into - and the practice of - precision medicine

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details

15:50 Networking break

Big Data and Genomics
16:40

Developing IT infrastructure to support the collection, storage, visualization and distribution of genomic, clinical and laboratory data

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Collaborations Across Precision Medicine
17:00

Getting the most from academic – industrial collaborations in the big data / AI space

  • Scoping the collaboration and contractual synergy – getting it right before you start
  • Key stakeholder alignment and investment – joint teams with a common vision
  • Investment in the future – short term goals are always good but ensuring a longer-term strategy provides confidence to generate the science and ensure the integrity of investigative outcomes
  • Track record of accountability – evidence generation
Big Data and Genomics
17:20

Improving the cyber security of your data system

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Collaborations Across Precision Medicine
17:20

Collaboration at scale: Pan-regional precision medicines across the North of England's 15m population

  • The Northern Health Science Alliance
  • An overview of the North of England’s health research environment
  • Precision medicine industry engagement at scale
  • Pioneering precision medicine initiatives ready for scale up
Big Data and Genomics
17:40

Large-scale genomics for therapeutics and prevention of cancer

  • Lessons from the Genomics England 100,000 Genomes Project
  • Pan genomic analyses move molecular testing upstream from the metastatic setting to primary diagnosis
  • High penetrance cancer susceptibility genes, common variants and non-genetic factors: integrated data analysis for risk profiling with which to target our resources for screening, prevention and early detection
Collaborations Across Precision Medicine
17:40

Collaboration in MedTech translation: academia, industry and the regulator

  • CÚRAM is an Irish national medical device research centre with industry partners
  • MMI is partnering with CÚRAM in developing resources to navigate the regulatory environment
  • This is well-aligned with the work of colleagues in developing methods of clinical and economic evaluation
Collaborations Across Precision Medicine
17:40

Collaboration in MedTech translation: academia, industry and the regulator

  • CÚRAM is an Irish national medical device research centre with industry partners
  • MMI is partnering with CÚRAM in developing resources to navigate the regulatory environment
  • This is well-aligned with the work of colleagues in developing methods of clinical and economic evaluation

18:00 End of Day 1 - Networking drinks reception

last published: 15/Dec/17 11:05 GMT

 

 

The World Precision Medicine Congress is both a world-class conference, bringing together hundreds of pharma, biotech and academic leaders from around the globe, and a fantastic exhibition showcasing the newest technologies, developments and solutions. There is a registration fee to attend the congress, however the exhibition is absolutely free to attend 

CONTACT US 
phone: +44 (0)207 092 1134 
email: 
  
joan.shutt@terrapinn.com